Skip to main content

がん免疫療法市場は世界的なビジネス予測2030年に急成長しています


The global cancer immunotherapy market was valued at $45,471 million in 2015, and is projected to reach $117,114 million by 2022, growing at a CAGR of 14.5% from 2016 to 2022. The monoclonal antibodies segment held two-third share of the total market in 2015.

Cancer immunotherapy, also known as biologic therapy, helps in cancer treatment by boosting the immunity of the body to fight against cancer. In this type of therapy antibodies and live viruses are introduced in the body that slows the growth of cancer cells. In addition, it also helps the immune system destroy the cancer cells. The major factors that drive the growth of this market include increase in incidence of cancers, growth in geriatric population, and rise in cancer R&D. However, shortage of skilled labor and lack of awareness about cancer immunotherapy is projected to restrain the market growth during the forecast period.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2244

The cancer immunotherapy market in this report is studied on the basis of technology, application, end-user, and region. Based on technology, the market is divided into monoclonal antibodies, cytokines & immunomodulators, and other technologies. Monoclonal antibodies held the largest share in 2015 owing to high usage of monoclonal antibodies for cancer immunotherapy as they exhibit different immunomodulatory properties and hence they can directly activate or inhibit the molecules of immune system. In addition, monoclonal antibodies also induce the antitumor immune response.

By application, the cancer immunotherapy market is segmented as lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. The lung cancer market held the largest share in 2015 and is expected to lead the market during the analysis period owing to high incidence of lung cancer. Hospitals in end users held the largest market share of cancer immunotherapy market in 2015, and is projected to show the highest growth rate during the analysis period due to the extensive use of cancer immunotherapy in the hospitals.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2244

Geographically, the global cancer immunotherapy market is analyzed by four regions, namely, North America, Europe, Asia-Pacific, and LAMEA. North America was the highest revenue contributor in 2015. This is attributed to the ample amount of expenditure in healthcare, well-established healthcare system, and high incidence of cancer. However, Asia-Pacific region is projected to be grow with the highest CAGR during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.

The Major Key Players Are:

Amgen Inc., Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., and Astrazeneca plc.

Key Findings of the Cancer Immunotherapy Market:

  • The monoclonal antibody accounted for the largest market share for technology segment in 2015 and is also estimated to grow at the highest CAGR of 15.0%.
  • By application, lung cancer held the highest market share and is anticipated to lead the market during the analysis period.
  • The U.S. was the major shareholder in the North American cancer immunotherapy market, accounting for six-seventh share in 2015.
  • China is expected to show the highest growth rate during the analysis period for the Asia-Pacific cancer immunotherapy market.

Access Full Report @ https://www.alliedmarketresearch.com/cancer-immunotherapy-market

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: 
https://www.alliedmarketresearch.com

Comments

Popular posts from this blog

放射線情報システム市場 is expected to reach $941 million by 2022, supported by a CAGR of 5.9%

T he radiology information system market was valued at  $603 million  in 2015, and is projected to reach  $941 million  by 2022, growing at a CAGR of 5.9% from 2016 to 2022. The integrated radiology information systems segment held over three-fifths share of the total market in 2015. Radiology information system (RIS) is a computer networked system used to organize and manage the workflow of medical imagery and radiology department, supporting business analysis in a department. RIS is widely used along with picture archiving and communication system (PACS) and vendor neutral archive to manage billing, record keeping, and image archives. The integrated radiology information systems held the largest share in 2015 and is expected to grow at the highest CAGR of 6.0% during the analysis period. This is owing to the surging adoption and demand of integrated healthcare information technology platforms in various healthcare organization for easy operations to curb over expe...

2027年までに9億8,330万ドルを獲得する心臓再同期療法市場

As per the report published by Allied Market Research, the   Cardiac Resynchronization Therapy Market   was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027. Download Sample Report at:  https://www.alliedmarketresearch.com/request-sample/10657 Rise in the geriatric population, increase in the prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market. Moreover, high-end technological developments in CRT devices supplemented the market growth. However, product recalls in the U.S., cost of CRT devices, and shortage of healthcare professionals hinder the market growth. On the contrary, developing opportunities in the low economic U.S. states would open lucrative opportunities for the market players. Covid-19 scenario- The integration of CRT pacemaker and cardiac resynchronization therapy defibrill...

組織工学市場 to Reach $6.81 Billion by 2027: Allied Market Research

As per the report published by Allied Market Research, the global  Tissue Engineering Market  generated $2.37 billion in 2019, and is projected to garner $6.81 billion by 2027, growing at a CAGR of 14.2% from 2020 to 2027. Rise in need for tissue engineering in organ transplantation, surge in prevalence of chronic diseases and trauma emergencies, and advancements in medical equipment technologies drive the growth of the global tissue engineering market. However, high cost associated with tissue engineered products hampers the market growth. On the contrary, untapped opportunities in the developing markets is expected to create lucrative opportunities in the future. Download Detailed COVID-19 Impact Sample Report at:  https://www.alliedmarketresearch.com/request-for-customization/4323?reqfor=covid Covid-19 scenario: Since the Covid-19 outbreak, clinical research in tissue engineering is temporarily suspended and the funds are redirected for clinical trials for the Covid-1...